Burren Christine P, Caswell Richard, Castle Bruce, Welch C Ross, Hilliard Tom N, Smithson Sarah F, Ellard Sian
Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Bristol Medical School Translational Health Sciences, University of Bristol, Bristol, United Kingdom.
Am J Med Genet A. 2018 Sep;176(9):1950-1955. doi: 10.1002/ajmg.a.40484. Epub 2018 Aug 25.
Transient receptor potential vanilloid 6 (TRPV6) functions in tetramer form for calcium transport. Until now, TRPV6 has not been linked with skeletal development disorders. An infant with antenatal onset thoracic insufficiency required significant ventilatory support. Skeletal survey showed generalized marked undermineralization, hypoplastic fractured ribs, metaphyseal fractures, and extensive periosteal reaction along femoral, tibial, and humeral diaphyses. Parathyroid hormone (PTH) elevation (53.4-101 pmol/L) initially suggested PTH signaling disorders. Progressively, biochemical normalization with radiological mineralization suggested recovery from in utero pathophysiology. Genomic testing was undertaken and in silico protein modeling of variants. No abnormalities in antenatal CGH array or UPD14 testing. Postnatal molecular genetic analysis found no causative variants in CASR, GNA11, APS21, or a 336 gene skeletal dysplasia panel investigated by whole exome sequencing. Trio exome analysis identified compound heterozygous TRPV6 likely pathogenic variants: novel maternally inherited missense variant, c.1978G > C p.(Gly660Arg), and paternally inherited nonsense variant, c.1528C > T p.(Arg510Ter), confirming recessive inheritance. p.(Gly660Arg) generates a large side chain protruding from the C-terminal hook into the interface with the adjacent TRPV6 subunit. In silico protein modeling suggests steric clashes between interface residues, decreased C-terminal hook, and TRPV6 tetramer stability. The p.(Gly660Arg) variant is predicted to result in profound loss of TRPV6 activity. This first case of a novel dysplasia features severe but improving perinatal abnormalities. The TRPV6 compound heterozygous variants appear likely to interfere with fetoplacental calcium transfer crucial for in utero skeletal development. Astute clinical interpretation of evolving perinatal abnormalities remains valuable in complex calcium and bone pathophysiology and informs exome sequencing interpretation.
瞬时受体电位香草酸亚型6(TRPV6)以四聚体形式发挥钙转运功能。到目前为止,TRPV6尚未与骨骼发育障碍相关联。一名产前发病的胸廓发育不全婴儿需要大量通气支持。骨骼检查显示全身明显矿化不足、肋骨发育不全性骨折、干骺端骨折以及股骨、胫骨和肱骨干广泛的骨膜反应。甲状旁腺激素(PTH)升高(53.4 - 101 pmol/L)最初提示PTH信号传导障碍。逐渐地,生化指标正常化以及放射学上的矿化表明从子宫内病理生理状态恢复。进行了基因组检测以及变异体的计算机蛋白质建模。产前比较基因组杂交阵列或14号染色体单亲二倍体检测未发现异常。产后分子遗传学分析在钙敏感受体(CASR)、鸟苷酸结合蛋白α亚基11(GNA11)、自身免疫性多内分泌病综合征2型(APS21)或通过全外显子测序研究的336个基因的骨骼发育异常相关基因面板中未发现致病变异体。三联体外显子分析鉴定出TRPV6的复合杂合可能致病变异体:新的母系遗传错义变异体,c.1978G>C p.(Gly660Arg),以及父系遗传的无义变异体,c.1528C>T p.(Arg510Ter),证实为隐性遗传。p.(Gly660Arg)产生一个从C末端钩突出到与相邻TRPV6亚基界面的大侧链。计算机蛋白质建模表明界面残基之间存在空间冲突、C末端钩减少以及TRPV6四聚体稳定性降低。预测p.(Gly660Arg)变异体将导致TRPV6活性严重丧失。这例新型发育异常的首例病例具有严重但逐渐改善的围产期异常特征。TRPV6复合杂合变异体似乎可能干扰对子宫内骨骼发育至关重要的胎盘 - 胎儿钙转运。在复杂的钙和骨病理生理过程中,对不断演变的围产期异常进行敏锐的临床解读仍然很有价值,并为外显子测序解读提供依据。